1007883-48-8

Upstream product

• 1007882-12-3 (S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1007883-42-2 (S)-tert-butyl 2-(5-(2-chloropyrimidin-5-yl)-1-((2-(trimethyl-silyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1007881-98-2 y 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 
• 1007883-29-5 2-bromo-1-(2-chloropyrimidin-5-yl)ethanone 
• 122372-20-7 2-chloro-5-(α-ethoxyvinyl)pyrimidine 
• 1007883-36-4 tert-butyl (2S)-2-[5-(2-chloropyrimidin-5-yl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.